Статья: СПОНДИЛОАРТРИТЫ И ВИЧИНФЕКЦИЯ, ОСОБЕННОСТИ ТЕЧЕНИЯ И ЛЕЧЕНИЯ (2025)

1. Клинические рекомендации. ВИЧ-инфекция у взрослых. 2020. URL: https://rushiv.ru/klinicheskie-rekomendatsii-vich-infektsiya-u-vzroslyh-2020/(дата обращения: 20.02.25.).
2. Заявление Минздрава России относительно серии публикаций о ситуации с ВИЧ. 2022. URL: https://minzdrav.gov.ru/news/2022/12/08/19630-zayavlenie-minzdrava-rossii-otnositelno-serii-publikatsiy-o-situatsii-s-vich (дата обращения: 20.02.25.).
3. Saigal R., Chakraborty A., Yadav R. N., Goyal L. K. Rheumatological Manifestations in HIV-Positive Patients: A Single-Center Study // Adv Ther. 2020. Vol. 37, № 10. P. 4336-45. DOI: 10.1007/s12325-020-01470-3
4. Гриднева Г. И., Белов Б. С. Актуальные вопросы ведения пациентов с ВИЧ-инфекцией и ревматическими заболеваниями // Современная ревматология. 2021. Т. 15, № 6. С. 7-12. DOI: 10.14412/1996-7012-2021-6-7-12
5. Mallon E. Bunker C. B. HIV-associated psoriasis // AIDS Patient Care STDS. 2000. Vol. 14. P. 239-246.
6. Duvic M., Johnson T. M., Rapini R. P. et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter’s syndrome // Arch Dermatol. 1987. Vol. 123. P. 1622-1632.
7. Эрдес Ш. Ф., Бадокин В. В., Бочкова А. Г. и др. О терминологии спондилоартритов // Научно-практическая ревматология. 2015. Т. 53, № 6. С. 657-660. DOI: 10.14412/1995-4484-2015-657-660
8. Sellam J., Bouvard B., Masson C. et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients // Joint Bone Spine. 2007. Vol. 74, № 2. P. 197-200.
9. Bartke U., Venten I., Kreuter A. et al. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab // Br J Dermatol. 2004. Vol. 150, № 4. P. 784-6. DOI: 10.1111/j.0007-0963.2004.05885.x
10. Lindsey S. F., Weiss J., Lee E. S., Romanelli P. Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient // Journal of Drugs in Dermatology: JDD. 2014. Vol. 13, № 7. P. 869-871.
11. Motolese A., Ceccarelli M., Macca L. et al. Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease // Biomedicines. 2022. Vol. 10, № 2. P. 228.
12. Romita P., Foti C., Calianno G., Chiricozzi A. et al. Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast // Dermatologic therapy. 2022. Vol. 35, № 8. P. e15610. DOI: 10.1111/dth.15610
13. Liu Y., Foreman S. C., Joseph G. B. et al. Is treated HIV infection associated with knee cartilage degeneration and structural changes? A longitudinal study using data from the osteoarthritis initiative // BMC Musculoskelet Disord. 2019. Vol. 20, № 1. P. 190. DOI: 10.1186/s12891-019-2573-5
14. Tomi A. L., Sellam J., Lacombe K. et al. Increased prevalence and severity of radiographic hand osteoarthritis in patients with HIV-1 infection associated with metabolic syndrome: data from the cross-sectional METAFIB-OA study // Ann Rheum Dis. 2016. Vol. 75, № 12. P. 2101-7. DOI: 10.1136/annrheumdis-2016-209262
15. Cepeda E. J., Williams F. M., Ishimori M. L. et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease // Ann Rheum Dis. 2008. Vol. 67, № 5. P. 710-2. DOI: 10.1136/ard.2007.081513
16. Paparizos V., Rallis E., Kirsten L., Kyriakis K. Ustekinumab for the treatment of HIV psoriasis // JDermatolog Treat. 2012. Vol. 23, № 6. P. 398-9. DOI: 10.3109/09546634.2011.579085
17. Saeki H., Ito T., Hayashi M. et al. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection // J Eur Acad Dermatol Venereol. 2015. Vol. 29. P. 1653-1655.
18. Yang J. J., Tsai M. S., Sun H. Y. et al. Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy // J Microbiol Immunol Infect. 2015. Vol. 48, № 2. P. 130-6. DOI: 10.1016/j.jmii.2013.08.002
19. Altman E. M., Centeno L. V., Mahal M., Bielory L. AIDS-associated Reiter’s syndrome // Ann Allergy. 1994. Vol. 72, № 4. P. 307-16. PMID: 8154628. PMID: 8154628
20. Qian F., Yan Y., Huang J. et al. Use of ixekizumab in an HIV-positive patient with psoriatic arthritis // Int J STD AIDS. 2022. Vol. 33, № 5. P. 519-521. DOI: 10.1177/09564624221076289
21. Bulbul R., Williams W. V., Schumacher H. R. Jr. Psoriatic arthritis. Diverse and sometimes highly destructive // Postgrad Med. 1995. Vol. 97, № 4. P. 97-9. Vol. 103-6. Vol. 108. PMID: 7716095. PMID: 7716095
22. Adizie T., Moots R. J., Hodkinson B. et al. Inflammatory arthritis in HIV positive patients: A practical guide // BMC Infect Dis. 2016. Vol. 16. P. 100. 10.1186/s12879-016-1389-2. PMID: 26932524; PMCID: PMC4774153. DOI: 10.1186/s12879-016-1389-2.;PMCID PMID: 26932524
23. Romero-Maté A., García-Donoso C., Córdoba-Guijarro S. EfÏcacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review // Am J Clin Dermatol. 2007. Vol. 8, № 3. P. 143-55. PMID: 17492843. DOI: 10.2165/00128071-200708030-00002. PMID: 17492843
24. Manfreda V., Esposito M., Campione E. et al. Apremilast efÏcacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections // Postgrad Med. 2019. Vol. 131, № 3. P. 239-240. DOI: 10.1080/00325481.2019.1575613
25. Youssef P. P., Bertouch J. V., Jones P. D. Successful treatment of human immunodeficiency virus-associated Reiter’s syndrome with sulfasalazine // Arthritis Rheum. 1992. Vol. 35. P. 723-4.
26. Mahajan A., Tandon V., Verma S. Rheumatological manifestations in HIV infection // JIACM. 2006. Vol. 7, № 2. P. 136-44.
27. Schläpfer E., Fischer M., Ott P., Speck R. F. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea // AIDS. 2003. Vol. 17, № 11. P. 1613-20.
28. Maganti R., Reveille J., Williams F. Therapy insight: the changing spectrum of rheumatic disease in HIV infection // Nat Clin Pract Rheumatol. 2008. Vol. 4. P. 428-38.
29. Yombi J. C., Maiter D., Belkhir L. et al. Iatrogenic Cushing’s syndrome and secondary adrenal insufÏciency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir // Clin Rheumatol. 2008. Vol. 27 Suppl 2. P. S79-82.
30. Aboulafia D. M., Bundow D., Wilske K., Ochs U. I. Etanercept for the treatment of human immunodeficiency virus associated arthritis // Mayo Clin Proc. 2000. Vol. 75. P. 1093-8.
31. Sacchelli L., Patrizi A., Ferrara F., Bardazzi F. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis // Dermatol Ther. 2018. Vol. 31, № 6. P. e12719. PMID: 30358044. DOI: 10.1111/dth.12719. PMID: 30358044
32. Vílchez-Oya F., Orpinell Palacio L., Castillo Vilella M. et al. The use of secukinumab in an HIV-positive patient with axial spondyloarthritis: a casebased review // Clin Rheumatol. 2021. Vol. 40, № 12. P. 5111-5114. DOI: 10.1007/s10067-021-05922-1
33. Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter’s syndrome // J Rheumatol. 2003. Vol. 30, № 2. P. 407-11. PMID: 12563704. PMID: 12563704
34. Gaylis N. B. Long-term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab // J Clin Rheumatol. 2012. Vol. 18, № 3. P. 153-4. PMID: 22426582. DOI: 10.1097/RHU.0b013e31824e9151. PMID: 22426582
35. Calabrese L. H., Zein N., Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection // Ann Rheum Dis. 2004. Vol. 63 Suppl 2, P. ii18-ii24. 10.1136/ard.2004.028209. PMID: 15479865; PMCID: PMC1766782. DOI: 10.1136/ard.2004.028209.;PMCID PMID: 15479865
36. Carroll M. B., Fields J. H., Clerc P. G. Rheumatoid arthritis in patients with HIV: management challenges // Open Access Rheumatol. 2016. Vol. 8. P. 51-59. 10.2147/OARRR.S87312. PMID: 27843370; PMCID: PMC5098761. DOI: 10.2147/OARRR.S87312.;PMCID PMID: 27843370
37. Walker-Bone K., Doherty E., Sanyal K., Churchill D. Assessment and management of musculoskeletal disorders among patients living with HIV // Rheumatology (Oxford). 2017. Vol. 56, № 10. P. 1648-1661. 10.1093/rheumatology/kew418. PMID: 28013196; PMCID: PMC5483171. DOI: 10.1093/rheumatology/kew418.;PMCID PMID: 28013196
38. Myers B., Thibodeaux Q., Reddy V. et al. Biologic Treatment of 4 HIV-Positive Patients. P. A Case Series and Literature Review // J Psoriasis Psoriatic Arthritis. 2021. Vol. 6, № 1. P. 19-26. 10.1177/2475530320954279. PMID: 35784673; PMCID: PMC9249044. DOI: 10.1177/2475530320954279.;PMCID PMID: 35784673
39. Bourinbaiar A. S., Lee-Huang S. The non-steroidal anti-inflammatory drg, indomethacin, as an inhibitor of HIV replication // FEBS Lett. 1995. Vol. 360, № 1. P. 85-8. , № 95)00057-g. PMID: 7875307. DOI: 10.1016/0014-5793 PMID: 7875307
40. Allegue F., Boixeda P., España A. et al. Síndrome de Reiter exacerbado por indometacina// Med Cutan Ibero Lat Am. 1989. Vol. 17, № 2. P. 113-6. Spanish. PMID: 2666796. PMID: 2666796
41. Stein C. M., Davis P. Arthritis associated with HIV infection in Zimbabwe // J Rheumatol. 1996. Vol. 23, № 3. P. 506-11. PMID: 8832993. PMID: 8832993
42. Pettersen F. O., Torheim E. A., Dahm A. E. et al. An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses // J Virol. 2011. Vol. 85, № 13. P. 6557-66. 10.1128/JVI.00073-11. PMID: 21490090; PMCID: PMC3126508. DOI: 10.1128/JVI.00073-11.;PMCID PMID: 21490090
43. Ulmer A., Müller M., Bertisch-Möllenhoff B., Frietsch B. Low dose prednisolone reduces CD4+ T cell loss in therapy-naive HIV-patients without antiretroviral therapy // Eur J Med Res. 2005. Vol. 10, № 3. P. 105-9. PMID: 15851376. PMID: 15851376
44. Ulmer A., Müller M., Bertisch-Möllenhoff B., Frietsch B. Low-dose prednisolone has a CD4-stabilizing effect in pre-treated HIV-patients during structured therapy interruptions (STI) // Eur J Med Res. 2005. Vol. 10, № 6. P. 227-32. PMID: 16033711. PMID: 16033711
45. Masson C., Chennebault J. M., Leclech C. Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis? // J Rheumatol. 1995. Vol. 22, № 11. P. 2191. PMID: 8596175. PMID: 8596175
46. Mody G. M., Parke F. A., Reveille J. D. Articular manifestations of human immunodeficiency virus infection // Best Pract Res Clin Rheumatol. 2003. Vol. 17, № 2. P. 265-87. PMID: 12787525. DOI: 10.1016/s1521-6942(03)00003-2. PMID: 12787525
47. Tarr G., Makda M., Musenge E., Tikly M. Effect of human immunodeficiency virus infection on disease activity in rheumatoid arthritis: a retrospective study in South Africans // J Rheumatol. 2014. Vol. 41, № 8. P. 1645-9. PMID: 25028384. DOI: 10.3899/jrheum.130896. PMID: 25028384
48. Tourne L., Durez P., Van Vooren J. P. et al. Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine // J Am Acad Dermatol. 1997. Vol. 37, № 3 Pt 1. P. 501-2. PMID: 9308575. DOI: 10.1016/s0190-9622(97)70160-9. PMID: 9308575
49. Galeazzi M., Giannitti C., Manganelli S. et al. Treatment of rheumatic diseases in patients with HCV and HIV infection // Autoimmun Rev. 2008. Vol. 8, № 2. P. 100-3. PMID: 18694850. DOI: 10.1016/j.autrev.2008.07.009. PMID: 18694850
50. Naovarat B. S., Salazar G., Ishimori M. et al. Biological treatment usage in patients with HIV and rheumatic disease, 2003-2021: long-term safety and follow-up // RMD Open. 2022. Vol. 8, № 2. P. e002282. 10.1136/rmdopen-2022-002282. PMID: 35863862; PMCID: PMC9310260. DOI: 10.1136/rmdopen-2022-002282.;PMCID EDN: HTBSMS PMID: 35863862
51. Foisy M. M., Yakiwchuk E. M., Chiu I., Singh A. E. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature // HIV Med. 2008. Vol. 9, № 6. P. 389-96. DOI: 10.1111/j.1468-1293.2008.00579.x
52. Kvale D., Ormaasen V., Kran A. M. et al. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment // AIDS. 2006. Vol. 20, № 6. P. 813-20. PMID: 16549964. DOI: 10.1097/01.aids.0000218544.54586.f1. PMID: 16549964
53. Prebensen C., Trøseid M., Ueland T. et al. Immune activation and HIVspecific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial // PLoS One. 2017. Vol. 12, № 5. P. e0176527. 10.1371/journal.pone.0176527. PMID: 28464042; PMCID: PMC5413033.